T
he sample size needed to determine whether a vaccine is, for example, at least 50% efficacious is often questioned. Although on the surface this question appears straightforward, it is not. To answer it properly, one must include the complexities of population disease-dynamics, where vaccine efficacy (VE) and proportion of the population vaccinated would affect the disease incidence proportion (IP). Although VE is independent of vaccinated proportion, IP is not. For example, if half of a population were vaccinated, and the IP in the nonvaccinated (IP nv ) and vaccinated (IP v ) groups was 0.4 and 0.2, respectively, the VE would be calculated as 1 
:
If, on the other hand, the vaccinated percentage were increased to 90%, perhaps the IP would be reduced to 0.02 and 0.01 for the nonvaccinated and vaccinated individuals, respectively, whereas VE remains constant at 50%. Therefore, depending on the disease transmission dynamics, VE, and vaccination level, IP may vary considerably.
Although it may be reassuring that VE is unaffected by the proportion of the population vaccinated and transmission dynamics, the sample size needed to evaluate the VE is highly dependent on these variables. Therefore, special consideration must be given to predict the disease incidence in the vaccinated and nonvaccinated groups in a population in which VE is being estimated.
The purpose of the study presented here was to compare a commonly used method for calculating absolute differences in proportions with a method better suited for evaluating VE and avoiding problems associated with evaluating a population-based vaccine trial.
Materials and Methods
Sample size selection is a relatively simple process in a randomized field trial where the outcome is a proportion and the use of a treatment in part of the population does not affect the incidence in untreated individuals. There are 3 components that need to be determined: power of the test (1 -β), desired significance level (α), and the difference between the 2 groups that is thought to be important. Common values for α range from 1 to 10%, whereas those for power range from 80 to 95%. Once these values are determined, the difference (d) in the 2 proportions that is thought to be important is then specified. For example, there may be interest in a product that reduces the proportion of an adverse outcome (eg, proportion of clinically affected animals, from 0.3 to 0.2, thus d = 0.1). Once α, β, and d are established, the necessary sample size (for each group) may be calculated, using the following equation 2 
:
where quantities Z and Z are values from the standard normal distribution corresponding to and p is the mean proportion, (p nv +p v )/2, and p nv and p v are the proportions in the nonvaccinated and vaccinated groups, respectively. Fleiss 3 introduced a correction for continuity factor (similar to the Yates correction factor for χ 2 tests), n + 2/|p nv -p v |, which provides a more conservative estimate of sample size. For tests of difference in proportions, such as those used in the evaluation of VE, it is common that a 2-sided Z value denotes the standard normal deviate corresponding to the probability value. Z α/2 is used to indicate a 2-tailed test of the difference. The 2-tailed test is used to provide for the possibility that the difference between the 2 groups may be either positive or negative. On the other hand, a 1-tailed test may be used for the power calculation if there are preliminary data indicating a beneficial vaccine 
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Objective-To determine the sample size necessary to evaluate the efficacy of a vaccine in a population. Procedure-An equation was coded into a computer spreadsheet to compare the traditional sample size calculation with that needed when evaluating the efficacy of a vaccine applied in a population. Results-The traditional approach used to conservatively estimate sample size necessary to detect a given difference in group proportions potentially greatly underestimates the number of animals needed for vaccine efficacy (VE) trials. In VE trials, it is necessary to estimate the effect of population-level vaccination prior to estimating sample size. In VE trials, as incidence proportion in the population or herd decreases or VE decreases, necessary sample size increases.
Conclusions and Clinical Relevance-In designing a clinical or field trial, such as one to evaluate the efficacy of a vaccine against an infectious disease in a population, one needs to approach sample size calculations in a nontraditional manner. The proportion of the population vaccinated, disease transmission dynamics, and VE will affect the incidence in the nonvaccinated and vaccinated groups and, hence, sample size. Thus, estimation of the effect of the vaccination on the population must be made prior to calculating sample size. Otherwise, sample size and the power to identify VE will be insufficient. (Am J Vet Res 2001;62:1582-1584)
effect. Using a 1-tailed test, the resulting significance is half that derived from a 2-tailed test (eg, 0.05 [1-tailed] vs 0.10 [2-tailed]). As a result, the 1-tailed test is more likely to result in significant findings and should be used only when justified. In specifying the type-I error, α, one is establishing the probability of falsely saying the IP between groups is significantly different. Secondly, the power is typically selected depending on the relative cost of making a type-II (β) versus type-I error. Cohen 4 offered a criterion whereby β is set 4 times greater than α. Thus, the probability of incorrectly indicating that an action does not reduce the risk of an adverse outcome is set at approximately 4 times the probability of incorrectly saying an action has an effect when in fact it does not. Common examples are α = 1%, β = 5% (power = 95%) and α = 5%, β = 20% (power = 80%).
The sample-size equation was coded into an electronic spreadsheet.
a In this medium, the equation was easily manipulated to evaluate a series of "what if" questions to determine the sample size for a variety of combinations of α, β, and d.
Results
When determining sample size when the outcome is a proportion, it is recommended that if the expected proportion is unknown, a conservative sample size estimate would assume a mean group proportion of 0.5. As the mean proportion deviates from 0.5, for a fixed difference in proportions, the necessary sample size diminishes (Fig 1) . If the mean IP were 0.5 (IP nv = 0.55 and IP v = 0.45), the sample size necessary to detect a difference of 0.1, assuming an α = 5% and power = 80%, would be 412. However, if the IP in the nonvaccinated (IP nv ) group were 0.15, to detect the same 0.1 decrease (IP v = 0.05), only 161 individuals would be needed in each group.
However, sample size calculation becomes more complicated when evaluating an intervention (eg, vaccinating a portion of a population against an infectious disease) that affects disease transmission in the population. For although VE is fixed, the difference in proportions (IP nv -IP v ) changes with the mean IP, which is in turn dependent on disease transmissibility, vaccination level, and VE. Specifically, sample size is inversely proportional to IP (Fig 2) . For example, assume a vaccine is 50% efficacious, and IP in a nonvaccinated population is expected to be 0.6. One could conclude that if a vaccine were applied in the population, the resulting IP in the vaccinated animals would decrease to 0.3. However, because of the direct and indirect effects of vaccination, 5 as the result of the vaccination reducing the susceptible population, IP should decrease in the nonvaccinated and vaccinated animals. Thus, as the result of vaccination, the IP in the nonvaccinated group could decrease to 0.1, whereas the expected IP in the vaccinated group would be 0.05, again assuming VE = 50%. As a result, the difference in proportions would be 0.05, not 0.3. The sample size necessary to detect the smaller difference would thus increase from 49 to 475/group (Table 1) , a nearly 10-fold increase. Traditional conservative sample size estimates are satisfactory when VE is high, and disease transmission is expected to be minimally affected by vaccination (ie, IP nv is high). However, for low to moderate VE vaccines applied in a population with a low to moderate IP nv , the traditional approach underestimates necessary sample size. The relationship between sample size and IP varies greatly, especially when VE is low.
As discussed, a determinant of sample size is power, in this example the probability of correctly concluding that a vaccine is efficacious. Sample size and power vary proportionally (Table 1 and 2) . Also, the cost of increasing power is proportionately higher when sample size is larger. For instance, when VE is ≤ 20% and IP nv is ≤ 0.7, an increased sample size of approximately 33% is required when power is increased from 80 to 90%, whereas an increased sample size of approximately 13 to 20% is required for the same power increase when VE ≥ 70% and IP nv ≥ 0.7. Results presented here may be used to evaluate the trade-off between increasing (decreasing) sample size and increasing (decreasing) the significance and power of the associated statistical tests. Such information is disease-specific, and no general recommendation should be made here. 
Discussion
The question of what sample size is needed to determine that a vaccine is at least 50% efficacious on a farm remains. One can now answer this question, at least conditionally, because the estimate depends on the expected disease incidence. If an infectious-disease vaccine were applied in a population, disease incidence would be dependent on the amount of direct and indirect protection afforded by the vaccine, which is in turn dependent on population size, VE, and amount of mixing, or infectious agent transmission. The expected incidence in a (partially or wholly) vaccinated population may be estimated by simulation modeling. 6 Such a model could be constructed if outbreak data were available in either a (wholly or partially) vaccinated or nonvaccinated population. In this way, a proper sample size may be calculated, which will increase the likelihood of properly designing a study to evaluate VE. The model used here represents a disease that is transmitted by direct contact and no other way. For more complicated diseases (eg, those with clinical and nonclinical cases) with multiple agent transmission modes, carrier states, and waning immunity, a more complicated model should be used to accurately predict the outcome of population-based vaccination. a EXCEL, Microsoft Corp, Redmond, Wash.
